Introduction {#Sec1}
============

The fatal infections caused by multiresistant pathogens have become the worldwide concern. In addition, the inappropriate prescription and misuse of antibiotics which led to the increased rate of hospitalization, illness and death in patients have driven infectious disease to global health catastrophic threat. Therefore, the development of efficient, potent and new compounds would be a highly desirable task \[[@CR1]--[@CR4]\].

The wide spectrum of activities and compelling chemistry of quinolones have made this bicyclic core attractive for researchers. The introduction of fluoroquinolones (FQs) as antibacterial agents in 1960s eradicated the infections caused by Gram-negative pathogens. Furthermore, the capability of new members to fight against Gram-positive bacteria resulted in successfully introduction of the popular class of antibiotics into the market \[[@CR5]--[@CR8]\]. DNA gyrase, topoisomerase IV and bacterial topoisomerase II enzymes are considered as targets of quinolone derivatives \[[@CR9]--[@CR13]\]. FQs consist of a 4-quinolone/naphthyridone-3-carboxylic acid heterocyclic core, a fluorine atom and a secondary amine group attached to the C-6 and -7 positions, respectively. The ongoing researches on quinolone and its analogues inaugurated nearly 10,000 analogues with promising antibacterial activities, opening up new horizons in the field of antibacterial chemotherapy \[[@CR14], [@CR15]\]. The C-7 position was subjected to various changes with hopes to find more potent and effective agents. Based on the previous extensive research in this field, the basic character of this position is significantly related to the observed activity against DNA gyrase \[[@CR16]\]. The lipophilicity of fluoroquinolones plays an important role in the penetration of these compounds into bacterial cells, indicating that increasing the lipophilic character at C-7 position may increase their activity. In this regard, the presence of a bulky group at the N-4 position of piperazine is permitted. Therefore, different derivatives containing 2-oxoethyl or 2-oximinoethyl derivative attached to the piperazine ring at C-7 position were synthesized \[[@CR13]\]. In addition, the attachment of thiophene \[[@CR17], [@CR18]\], furan \[[@CR19]\], substituted phenyl \[[@CR20]\] and coumarin \[[@CR21], [@CR22]\] to piperazine ring was also investigated by our research team. In continuation of our expertise in this field \[[@CR23]--[@CR25]\], we report some novel analogues of sarafloxacin **3**, possessing α-haloketones- **(1a-f)**, hydroxyimino- **(2 g-l)**, methoxyimino- **(2 m-r)** and benzyloxyimino **(2 s-x)**-functionalized piperazine as C-7 substituents and evaluate their antibacterial activity against Gram-positive and Gram-negative bacteria.

Methods {#Sec2}
=======

Materials {#Sec3}
---------

All chemicals and solvents were obtained from Merck and Aldrich and used without further purification. Melting points were determined on a Kofler hot stage apparatus and are uncorrected. Shimadzu 470 spectrophotometer (potassium bromide disks) was used to record the IR spectra. ^1^H- and ^13^C-NMR spectra were recorded on Bruker FT-500 (Germany), using TMS as an internal standard. Elemental analyses were measured by CHN-O-rapid elemental analyzer (GmbH-Germany).

### General procedure for the synthesis of compounds 4a-x {#FPar1}

A mixture of compounds **(1a-f)** or **(2 g-x)** (0.55 mmol), sarafloxacin (**3**) (0.5 mmol) and NaHCO~3~ (0.5 mmol) in DMF (5 mL) was stirred at room temperature for 3--7 days. After consumption of sarafloxacin (**3)**, monitored by TLC, water (20 mL) was added and the precipitate was filtered, washed with water. For further purification, the products were recrystallized from CH~3~OH/CHCl~3~ to afford target compounds **4a**-**x**.

### 6-Fluoro-1-(4-fluorophenyl)-4-oxo-7-(4-(2-oxo-2-phenylethyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (**4a**) {#Sec4}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.65 (bs, 4H, piperazine), 3.07 (bs, 4H, piperazine), 3.37 (s, 2H), 6.39 (d, ^4^*J*~*H-F*~ = 7.5 Hz, 1H, aromatic), 7.30--7.33 (m, 3H, aromatic), 7.52--7.58 (m, 3H, aromatic), 7.78--7.79 (m, 3H, aromatic), 7.98 (d, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 8.64 (s, 1H, aromatic), 11.35 (s, 1H, COOH).. IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1722, 1672, 1622 (C=O). Anal. Calcd. For C~28~H~23~F~2~N~3~O~4~: C: 66.79; H: 4.60; N: 8.35; Found: C: 66.50; H: 4.82; N: 8.15.

### 6-Fluoro-1-(4-fluorophenyl)-7-(4-(2-(4-fluorophenyl)-2-oxoethyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**4b**) {#Sec5}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.63--2.67 (m, 4H, piperazine), 3.05--3.10 (m, 4H, piperazine), 3.86 (s, 2H), 6.39 (d, ^3^*J*~*H-F*~ = 7.5 Hz, 1H, aromatic), 7.32 (t, *J* = 9 Hz, 2H, aromatic), 7.52 (t, *J* = 8.5 Hz, 2H, aromatic), 7.76--7.79 (m, 2H, aromatic), 7.97 (d, *J* = 13 Hz, 1H, aromatic), 8.05--8.08 (m, 2H, aromatic), 8.62 (s, 1H, aromatic), 11.21 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1716, 1661, 1618 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 49.0, 52.0 (CH~2~ piperazine), 63.4 (CH~2~), 106.4, 107.2, 111.0 (d, ^3^*J*~C-F~ = 23.75 Hz), 115.5 (d, ^3^*J*~C-F~ = 21.25 Hz), 117.2 (d, ^3^*J*~C-F~ = 22.5 Hz), 119.0, 121.3, 129.8 (d, ^1^*J*~C-F~ = 7.5 Hz), 131.2 (d, ^1^*J*~C-F~ = 8.75 Hz), 132.4, 136.1, 139.1, 145.2, 148.6, 152.0, 154.0, 165.7 (COOH), 176.6 (C=O), 195.4. Anal. Calcd. For C~28~H~22~F~3~N~3~O~4~: C: 64.49; H: 4.25; N: 8.06; C: 64.72; H: 4.47; N: 7.85.

### 7-(4-(2-(4-Chlorophenyl)-2-oxoethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**4c**) {#Sec6}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.63--2.68 (m, 4H, piperazine), 3.06--3.12 (m, 4H, piperazine), 3.86 (s, 2H), 6.39 (d, ^4^*J*~*H-F*~ = 7.5 Hz, 1H, aromatic), 7.52 (t, *J* = 8 Hz, 2H, aromatic), 7.57 (d, *J* = 8.5 Hz, 2H, aromatic), 7.76--7.79 (m, 2H, aromatic), 7.96--8.02 (m, 3H, aromatic), 8.62 (s, 1H, aromatic), 10.20 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3590--3300 (OH), 1725, 1679, 1619 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 48.9, 51.9 (CH~2~ piperazine), 63.3 (CH~2~), 106.3, 107.0, 111.0 (d, ^3^*J*~C-F~ = 22.5 Hz), 117.1 (d, ^3^*J*~C-F~ = 22.5 Hz), 119.0, 128.5, 129.7, 129.9 (d, ^1^*J*~C-F~ = 7.5 Hz), 130.0, 134.1, 136.1, 138.0, 139.1, 145.2, 149.3, 153.7, 165.6 (COOH), 178.1 (C=O), 196.6. Anal. Calcd. For C~28~H~22~ClF~2~N~3~O~4~: C: 62.52; H: 4.12; N: 7.81; C: 62.80; H: 4.39; N: 7.59.

### 7-(4-(2-(4-Bromophenyl)-2-oxoethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**4d**) {#Sec7}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.30--2.35 (m, 4H, piperazine), 3.01--3.07 (m, 4H, piperazine), 3.30 (s, 2H), 6.39 (d, ^4^*J*~*H-F*~ = 6 Hz, 1H, aromatic), 7.53--7.54 (m, 2H, aromatic), 7.74--7.79 (m, 3H, aromatic), 7.83 (s, 1H, aromatic), 7.88--7.93 (m, 2H, aromatic), 8.01--8.03 (m, 1H, aromatic), 8.64 (s, 1H, aromatic), 10.66 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1722, 1666, 1621 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 49.1, 52.0 (CH~2~ piperazine), 63.0 (CH~2~), 106.5, 107.3, 111.0 (d, ^1^*J*~C-F~ = 23.75 Hz), 117.2 (d, ^3^*J*~C-F~ = 22.5 Hz), 119.0, 128.0, 128.6, 129.5, 129.8 (d, ^1^*J*~C-F~ = 7.5 Hz), 133.4, 136.4, 139.4, 146.2, 148.8, 152.5, 154.0, 165.8 (COOH), 176.8 (C=O), 197.3. Anal. Calcd. For C~28~H~22~BrF~2~N~3~O~4~: C: 57.74; H: 3.81; N: 7.22; C: 58.00; H: 3.54; N: 7.59.

### 6-Fluoro-1-(4-fluorophenyl)-4-oxo-7-(4-(2-oxo-2-(p-tolyl)ethyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (**4e**) {#Sec8}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.39 (s, 3H, CH~3~), 2.64 (bs, 4H, piperazine), 3.01 (bs, 4H, piperazine), 3.84 (s, 2H), 6.39 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.30 (d, *J* = 8 Hz, 2H, aromatic), 7.50--7.53 (m, 2H, aromatic), 7.76 (d, *J* = 7.5 Hz, 2H, aromatic), 7.87 (t, *J* = 6.5 Hz, 2H, aromatic), 7.96 (d, ^3^*J*~*H-F*~ = 12.5 Hz, 1H, aromatic), 8.61 (s, 1H, aromatic), 11.77 (s, 1H, COOH).. IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1716, 1661, 1618 (C=O). Anal. Calcd. For C~29~H~25~F~2~N~3~O~4~: C: 67.30; H: 4.87; N: 8.12; C: 67.55; H: 7.51; N: 8.39.

### 7-(4-(2-(2,4-Dichlorophenyl)-2-oxoethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**4f**) {#Sec9}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.62 (bs, 4H, piperazine), 3.02 (bs, 4H, piperazine), 3.76 (s, 2H), 6.38 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.54--7.58 (m, 3H, aromatic), 7.72--7.84 (m, 3H, aromatic), 7.96 (d, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 8.00 (t, *J* = 7.5 Hz, 1H, aromatic), 8.63 (s, 1H, aromatic), 12.10 (s, 1H, COOH).. IR (KBr cm^−1^), *ṽ* = 3585--3300 (OH), 1720, 1680, 1620 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 48.9, 51.8 (CH~2~ piperazine), 65.8 (CH~2~), 104.3, 106.6, 107.8, 111.0 (d, ^3^*J*~C-F~ = 22.5 Hz), 117.2 (d, ^3^*J*~C-F~ = 22.5 Hz), 119.0, 127.4, 129.8 (d, ^1^*J*~C-F~ = 7.5 Hz), 130.7, 131.0, 136.1, 139.1, 139.8, 146.0, 148.7, 154.0, 161.2, 162.2, 165.8 (COOH), 177.3 (C=O), 196.6. Anal. Calcd. For C~28~H~21~Cl~2~F~2~N~3~O~4~: C: 58.75; H: 3.70; N: 7.34; C: 59.00; H: 3.47; N: 7.64.

### 6-Fluoro-1-(4-fluorophenyl)-7-(4-(2-(hydroxyimino)-2-phenylethyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**4 g**) {#Sec10}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.98 (bs, 8H, piperazine), 3.65 (s, 2H), 6.37 (s, 1H, aromatic), 7.34--7.40 (m, 3H, aromatic), 7.51--7.58 (m, 3H, aromatic), 7.75--7.80 (m, 3H, aromatic), 7.95 (d, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 8.62 (s, 1H, aromatic), 10.96 (s, 1H, NOH), 11.44 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1718, 1618 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 49.8, 52.0 (CH~2~ piperazine), 61.2 (CH~2~), 106.5, 107.4, 110.9 (d, ^3^*J*~C-F~ = 23.75 Hz), 117.2 (d, ^3^*J*~C-F~ = 23.75 Hz), 119.0, 126.1, 127.7, 128.4 (d, ^1^*J*~C-F~ = 7.5 Hz), 129.8, 133.5, 136.1, 139.1, 145.1, 148.6, 152.6, 155.0, 161.5 (C=N), 165.7 (COOH), 176.6 (C=O). Anal. Calcd. For C~28~H~24~F~2~N~4~O~4~: C: 64.86; H: 4.67; N: 10.81; C: 65.09; H: 4.40; N: 11.03.

### 6-Fluoro-1-(4-fluorophenyl)-7-(4-(2-(4-fluorophenyl)-2-(hydroxyimino)ethyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**4 h**) {#Sec11}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.97--3.04 (m, 4H, piperazine), 3.17--3.21 (m, 4H, piperazine), 3.65 (s, 2H), 6.36 (s, 1H, aromatic), 7.41 (t, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 7.51--7.53 (m, 3H, aromatic), 7.64 (d, *J* = 7.5 Hz, 1H, aromatic), 7.76 (s, 3H, aromatic), 7.95 (d, *J* = 12 Hz, 1H, aromatic), 8.62 (s, 1H, aromatic), 11.14 (s, 1H, NOH), 11.57 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3585--3300 (OH), 1720, 1620 (C=O). Anal. Calcd. For C~28~H~23~F~3~N~4~O~4~: C: 62.68; H: 4.32; N: 10.44; C: 62.40; H: 4.05; N: 10.63.

### 7-(4-(2-(4-Chlorophenyl)-2-(hydroxyimino)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4i) {#Sec12}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.70--2.79 (m, 4H, piperazine), 3.06--3.11 (m, 4H, piperazine), 3.87 (s, 2H), 6.42 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.53 (t, *J* = 8 Hz, 2H, aromatic), 7.57 (d, *J* = 8.5 Hz, 1H, aromatic), 7.68 (d, *J* = 8.5 Hz, 1H, aromatic), 7.73--7.80 (m, 2H, aromatic), 7.92 (d, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 7.97--8.02 (m, 2H, aromatic), 8.63 (s, 1H, aromatic), 11.14 (s, 1H, NOH), 11.57 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3600--3300 (OH), 1719, 1620 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 49.7, 51.9 (CH~2~ piperazine), 61.0 (CH~2~), 106.5, 107.3, 111.0 (d, ^3^*J*~C-F~ = 23.75 Hz), 117.2 (d, ^3^*J*~C-F~ = 22.5 Hz),127.7, 128.0, 129.8 (d, ^1^*J*~C-F~ = 10 Hz), 130.4, 133.1, 134.7, 136.1, 139.1, 145.1, 148.6, 151.9, 155.0, 161.6 (C=N), 165.7 (COOH), 176.6 (C=O). Anal. Calcd. For C~28~H~23~ClF~2~N~4~O~4~: C: 60.82; H: 4.19; N: 10.13; C: 60.63; H: 3.89; N: 10.40.

### 7-(4-(2-(4-Bromophenyl)-2-(hydroxyimino)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4j) {#Sec13}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.98--3.05 (m, 4H, piperazine), 3.17--3.22 (m, 4H, piperazine), 3.69 (s, 2H), 6.36 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.55--7.56 (m, 2H, aromatic), 7.96--7.74 (m, 3H, aromatic), 7.58 (s, 1H, aromatic), 7.90--7.95 (m, 2H, aromatic), 8.03 (t, *J* = 7 Hz, 1H, aromatic), 8.63 (s, 1H, aromatic), 11.19 (s, 1H, NOH), 11.60 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3590--3300 (OH), 1725, 1619 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 49.0, 52.2 (CH~2~ piperazine), 61.0 (CH~2~), 106.5, 107.3, 111.0, 117.2 (d, ^3^*J*~C-F~ = 22.5 Hz), 119.0, 122.0, 128.2, 129.8 (d, ^1^*J*~C-F~ = 7.5 Hz), 130.6, 131.0, 136.1, 139.1, 145.1, 148.6, 152.0, 155.1, 161.2 (C=N), 165.7 (COOH), 176.6 (C=O). Anal. Calcd. For C~28~H~23~BrF~2~N~4~O~4~: C: 56.29; H: 3.88; N: 9.38; C: 56.03; H: 3.59; N: 9.54.

### 6-Fluoro-1-(4-fluorophenyl)-7-(4-(2-(hydroxyimino)-2-(p-tolyl)ethyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4 k) {#Sec14}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.23 (s, 3H), 2.92--3.09 (m, 8H, piperazine), 3.61 (s, 2H), 6.36 (d, ^4^*J*~*H-F*~ = 7.5 Hz, 1H, aromatic), 7.32 (d, *J* = 8 Hz, 2H, aromatic), 7.53--7.65 (m, 2H, aromatic), 7.78 (d, *J* = 7.5 Hz, 2H, aromatic), 7.89 (t, *J* = 7.5 Hz, 2H, aromatic), 7.96 (d, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 8.64 (s, 1H, aromatic), 11.12 (s, 1H, NOH), 11.40 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3590--3300 (OH), 1719, 1618 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 20.8 (CH~3~), 47.0, 49.0 (CH~2~ piperazine), 52.4 (CH~2~), 106.5, 107.4, 111.0 (d, ^3^*J*~C-F~ = 23.75 Hz), 117.3 (d, ^3^*J*~C-F~ = 22.5 Hz), 119.1, 126.1, 128.8, 129.9 (d, ^1^*J*~C-F~ = 7.5 Hz), 131.5, 133.5, 136.1, 139.1, 143.1, 148.8, 150.0, 154.5, 161.6 (C=N), 165.7 (COOH), 176.7 (C=O). Anal. Calcd. For C~29~H~26~F~2~N~4~O~4~: C: 65.41; H: 4.92; N: 10.52; C: 65.18; H: 5.19; N: 10.82.

### 7-(4-(2-(2,4-Dichlorophenyl)-2-(hydroxyimino)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4 l) {#Sec15}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.98--3.19 (m, 8H, piperazine), 3.65 (s, 2H), 6.37 (s, 1H, aromatic), 7.26 (m, 1H, aromatic), 7.43--7.48 (m, 1H, aromatic), 7.52 (t, *J* = 5.5 Hz, 2H, aromatic), 7.63 (s, 1H, aromatic), 7.70--7.77 (m, 2H, aromatic), 7.96 (d, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 8.63 (s, 1H, aromatic), 11.15 (s, 1H, NOH), 11.48 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1716, 1618 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) 훅 (ppm): 49.0, 52.1 (CH~2~ piperazine), 61.0 (CH~2~), 106.5, 107.3, 111.4 (d, ^3^*J*~C-F~ = 22.5 Hz), 117.3 (d, ^3^*J*~C-F~ = 22.5 Hz), 119.0, 127.1, 128.6, 128.2, 129.8 (d, ^1^*J*~C-F~ = 7.5 Hz), 131.2, 133.4, 136.1, 139.1 (2C), 146.1, 148.7, 152.0, 154.0, 161.5 (C=N), 165.7 (COOH), 176.6 (C=O). Anal. Calcd. For C~28~H~22~Cl~2~F~2~N~4~O~4~: C: 57.25; H: 3.78; N: 9.54; C: 57.00; H: 3.98; N: 9.21.

### 6-Fluoro-1-(4-fluorophenyl)-7-(4-(2-(methoxyimino)-2-phenylethyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4 m) {#Sec16}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.90--3.00 (m, 8H, piperazine), 3.64 (s, 2H), 3.90 (s, 3H, NOCH~3~), 6.35 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.36--7.39 (s, 3H, aromatic), 7.50 (t, *J* = 8.5 Hz, 2H, aromatic), 7.73--7.75 (m, 4H, aromatic), 7.96 (d, ^3^*J*~*H-F*~ = 13.5 Hz, 1H, aromatic), 8.62 (s, 1H, aromatic), 15.14 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3625--3250 (OH), 1724, 1623 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 49.0, 50.4 (CH~2~ piperazine), 52.2 (CH~2~), 61.7 (OCH~3~), 106.2, 107.1, 111.1 (d, ^3^*J*~C-F~ = 23.75 Hz), 117.2 (d, ^3^*J*~C-F~ = 23.75 Hz), 118.0, 126.5, 128.1, 129.0, 129.8 (d, ^1^*J*~C-F~ = 8.75 Hz), 134.8, 136.1, 139.1, 146.0, 146.8, 152.0, 153.9, 163.7 (C=N), 165.8 (COOH), 176.8 (C=O). Anal. Calcd. For C~29~H~26~Cl~2~F~2~N~4~O~4~: C: 65.41; H: 4.92; N: 10.52; C: 65.19; H: 5.11; N: 10.80.

### 6-Fluoro-1-(4-fluorophenyl)-7-(4-(2-(4-fluorophenyl)-2-(methoxyimino)ethyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4n) {#Sec17}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.90--2.99 (m, 8H, piperazine), 3.63 (s, 2H), 3.90 (s, 3H, NOCH~3~), 6.35 (d, ^4^*J*~*H-F*~ = 6.5 Hz, 1H, aromatic), 7.19--7.21 (m, 2H, aromatic), 7.51--7.53 (m, 2H, aromatic), 7.77--7.79 (m, 4H, aromatic), 7.96 (d, ^3^*J*~*H-F*~ = 12.5 Hz, 1H, aromatic), 8.62 (s, 1H, aromatic), 15.10 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3600--3250 (OH), 1713, 1619 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 49.0, 50.4 (CH~2~ piperazine), 52.1 (CH~2~), 61.8 (OCH~3~), 106.7, 107.7, 111.1 (d, ^3^*J*~C-F~ = 23.75 Hz), 115.0 (d, ^3^*J*~C-F~ = 23.75 Hz), 117.2 (d, ^3^*J*~C-F~ = 23.75 Hz), 122.1, 128.8 (d, ^1^*J*~C-F~ = 8.75 Hz), 129.8 (d, ^1^*J*~C-F~ = 8.75 Hz), 131.2, 136.2, 139.4 (2C), 146.0, 148.6, 153.0, 158.2, 161.8 (C=N), 176.4 (COOH), 179.6 (C=O). Anal. Calcd. For C~29~H~25~F~3~N~4~O~4~: C: 63.27; H: 4.58; N: 10.18; C: 63.01; H: 4.84; N: 9.94.

### 7-(4-(2-(4-Chlorophenyl)-2-(methoxyimino)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4o) {#Sec18}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.87--2.95 (m, 8H, piperazine), 3.60 (s, 2H), 3.90 (s, 3H, NOCH~3~), 6.22 (d, ^4^*J*~*H-F*~ = 6.5 Hz, 1H, aromatic), 7.36--7.37 (m, 1H, aromatic), 7.41--7.42 (m, 1H, aromatic), 7.46--7.49 (m, 1H, aromatic), 7.62--7.64 (m, 3H, aromatic), 7.73--7.78 (m, 3H, aromatic), 8.08 (s, 1H, aromatic), 15.15 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3585--3300 (OH), 1720, 1620 (C=O). Anal. Calcd. For C~29~H~25~ClF~2~N~4~O~4~: C: 61.43; H: 4.44; N: 9.88; C: 61.68; H: 4.21; N: 10.09.

### 7-(4-(2-(4-Bromophenyl)-2-(methoxyimino)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4p) {#Sec19}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.83--2.90 (m, 8H, piperazine), 3.63 (s, 2H), 3.95 (s, 3H, NOCH~3~), 6.24 (d, ^4^*J*~*H-F*~ = 6.5 Hz, 1H, aromatic), 7.38--7.39 (m, 2H, aromatic), 7.49--7.55 (m, 3H, aromatic), 7.65 (s, 1H, aromatic), 7.71--7.75 (m, 2H, aromatic), 7.83 (t, *J* = 6.5 Hz, 1H, aromatic), 8.60 (s, 1H, aromatic), 15.18 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1716, 1618 (C=O). Anal. Calcd. For C~29~H~25~BrF~2~N~4~O~4~: C: 56.97; H: 4.12; N: 9.16; C: 57.10; H: 3.95; N: 8.99.

### 6-Fluoro-1-(4-fluorophenyl)-7-(4-(2-(methoxyimino)-2-(p-tolyl)ethyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4q) {#Sec20}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.44 (s, 3H, CH~3~), 2.86--2.94 (m, 8H, piperazine), 3.60 (s, 2H), 3.91 (s, 3H, NOCH~3~), 6.31 (d, ^4^*J*~*H-F*~ = 6.5 Hz, 1H, aromatic), 7.34 (d, *J* = 7.5 Hz, 2H, aromatic), 7.52--7.57 (m, 2H, aromatic), 7.78 (d, *J* = 7 Hz, 2H, aromatic), 7.89 (t, *J* = 6 Hz, 2H, aromatic), 7.94 (d, ^3^*J*~*H-F*~ = 12.5 Hz, 1H, aromatic), 8.65 (s, 1H, aromatic), 15.25 (1H, COOH). IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1722, 1622 (C=O). Anal. Calcd. For C~30~H~28~F~2~N~4~O~4~: C: 65.92; H: 5.16; N: 10.25; C: 66.11; H: 5.01; N: 10.51.

### 7-(4-(2-(2,4-Dichlorophenyl)-2-(methoxyimino)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4r) {#Sec21}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.85--2.91 (m, 8H, piperazine), 3.61 (s, 2H), 3.94 (s, 3H, NOCH~3~), 6.30 (d, ^4^*J*~*H-F*~ = 6.5 Hz, 1H, aromatic), 7.42--7.46 (m, 2H, aromatic), 7.52 (t, *J* = 8 Hz, 2H, aromatic), 7.63 (s, 1H, aromatic), 7.73--7.75 (m, 2H, aromatic), 7.94 (d, ^3^*J*~*H-F*~ = 12.5 Hz, 1H, aromatic), 8.61 (s, 1H, aromatic), 15.11 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3590--3300 (OH), 1725, 1619 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 48.8, 52.4 (CH~2~ piperazine), 53.4 (CH~2~), 61.9 (OCH~3~), 106.4, 107.3, 111.4 (d, ^3^*J*~C-F~ = 23.75 Hz), 117.3 (d, ^3^*J*~C-F~ = 23.75 Hz), 123.0, 126.9, 128.7, 129.8 (d, ^1^*J*~C-F~ = 8.75 Hz), 132.2, 133.3 (2C), 133.7, 136.0, 139.0, 146.0, 148.5, 151.0, 155.8, 163.2 (C=N), 166.1 (COOH), 176.43 (C=O). Anal. Calcd. For C~29~H~24~Cl~2~F~2~N~4~O~4~: C: 57.91; H: 4.02; N: 9.32; C: 57.78; H: 3.88; N: 9.60.

### 7-(4-(2-((Benzyloxy)imino)-2-phenylethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4 s) {#Sec22}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.93--3.05 (m, 8H, piperazine), 3.67 (s, 2H), 5.18 (s, 2H, NOCH~2~), 6.34 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.19 (t, *J* = 8.5 Hz, 2H, aromatic), 7.31 (d, *J* = 7 Hz, 1H, aromatic), 7.35--7.40 (m, 5H, aromatic), 7.51 (t, *J* = 5.5 Hz, 2H, aromatic), 7.76--7.78 (m, 4H, aromatic), 7.96 (d, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 8.62 (s, 1H, aromatic), 10.11 (s, 1H, COOH). IR (KBr) cm^−1^; ***ν***: 3590--3300 (OH), 1719, 1618 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 48.9, 50.3 (CH~2~ piperazine), 52.1 (CH~2~), 75.8 (OCH~2~), 106.4, 107.3, 111.0 (d, ^3^*J*~C-F~ = 23.5 Hz), 117.2 (d, ^3^*J*~C-F~ = 23.75 Hz), 118.0, 122.5, 127.8, 128.1, 128.3, 128.6, 129.1, 129.8 (d, ^1^*J*~C-F~ = 7.5 Hz), 131.1, 133.9, 136.1, 137.4, 139.1, 146.0, 148.8, 153.6, 163.0 (C=N), 165.6 (COOH), 177.1 (C=O). Anal. Calcd. For C~35~H~30~F~2~N~4~O~4~: C: 69.07; H: 4.97; N: 9.21; C: 69.30; H: 5.11; N: 9.50.

### 7-(4-(2-((Benzyloxy)imino)-2-(4-fluorophenyl)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4 t) {#Sec23}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.93--2.99 (m, 8H, piperazine), 3.68 (s, 2H), 5.19 (s, 2H), 5.19 (s, 2H, NOCH~2~), 6.33 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.30--7.39 (m, 5H, aromatic), 7.50 (t, *J* = 8 Hz, 2H, aromatic), 7.71--7.75 (m, 4H, aromatic), 7.94 (d, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 8.62 (s, 1H, aromatic), 11.22 (s, 1H, COOH) IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1718, 1619 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 48.9, 50.5 (CH~2~ piperazine), 52.2 (CH~2~), 75.7 (OCH~2~), 106.5, 111.5 (d, ^3^*J*~C-F~ = 21.25 Hz), 115.0 (d, ^3^*J*~C-F~ = 21.25 Hz), 117.2 (d, ^3^*J*~C-F~ = 23.75 Hz), 118.0, 127.8, 128.1, 128.7 (d, ^1^*J*~C-F~ = 7.5 Hz), 131.2 (d, ^1^*J*~C-F~ = 6.5 Hz), 131.5, 132.3, 135.0, 136.1, 137.5, 139.5, 145.4, 148.7, 153.5, 154.0, 159.3, 163.9 (C=N), 166.5 (COOH), 177.1 (C=O). Anal. Calcd. For C~35~H~29~F~3~N~4~O~4~: C: 67.09; H: 4.66; N: 8.94; C: 67.25; H: 4.80; N: 9.11.

### 7-(4-(2-((Benzyloxy)imino)-2-(4-chlorophenyl)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,ν4-dihydroquinoline-3-carboxylic acid (4u) {#Sec24}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.84--2.90 (m, 4H, piperazine), 2.92--3.00 (m, 4H, piperazine), 3.68 (s, 2H), 5.23 (s, 2H, NOCH~2~), 6.33 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.31 (d, *J* = 8 Hz, 2H, aromatic), 7.36--7.42 (m, 4H, aromatic), 7.47--4.53 (m, 2H, aromatic), 7.62 (d, *J* = 7.5 Hz, 2H, aromatic), 7.73--7.79 (m, 2H, aromatic), 7.96 (d, ^3^*J*~*H-F*~ = 12.5 Hz, 1H, aromatic), 8.08 (s, 1H, aromatic), 8.62 (s, 1H, aromatic), 15.12 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1718, 161 (C=O). Anal. Calcd. For C~35~H~29~ClF~2~N~4~O~4~: C: 65.37; H: 4.55; N: 8.71; C: 65.10; H: 4.41; N: 8.94.

### 7-(4-(2-((Benzyloxy)imino)-2-(4-bromophenyl)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4v) {#Sec25}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.92--3.09 (m, 8H, piperazine), 3.67 (bs, 2H), 5.19 (s, 1H, NOCH~2~), 6.33 (s, 1H, aromatic), 7.36--7.42 (m, 4H, aromatic), 7.51--7.55 (m, 4H, aromatic), 7.67 (d, *J* = 8 Hz, 2H, aromatic), 7.76--7.79 (m, 2H, aromatic), 7.94 (d, ^3^*J*~*H-F*~ = 12 Hz, 1H, aromatic), 8.09--8.11 (m, 2H, aromatic), 8.62 (s, 1H, aromatic), 15.10 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1712, 1620 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 48.9, 50.3 (CH~2~ piperazine), 52.1 (CH~2~), 75.8 (OCH~2~), 106.4, 107.3, 111.0 (d, ^3^*J*~C-F~ = 23.5 Hz), 117.2 (d, ^3^*J*~C-F~ = 23.75 Hz), 118.0, 122.5, 127.8, 128.1, 128.3, 128.6, 129.1, 129.8 (d, ^1^*J*~C-F~ = 7.5 Hz), 131.1, 133.9, 136.1, 137.4, 139.1, 146.0, 148.8, 153.6, 163.0 (C=N), 165.6 (COOH), 177.1 (C=O). Anal. Calcd. For C~35~H~29~BrF~2~N~4~O~4~: C: 61.14; H: 4.25; N: 8.15; C: 61.33; H: 4.01; N: 8.32.

### 7-(4-(2-((Benzyloxy)imino)-2-(p-tolyl)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4w) {#Sec26}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.23 (s, 3H, CH~3~), 2.99--3.11 (m, 4H, piperazine), 2.84--2.89 (m, 4H, piperazine), 3.64 (s, 2H), 5.35 (s, 2H, NOCH~2~), 6.20 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.08 (d, *J* = 8 Hz, 1H, aromatic), 7.15 (d, *J* = 7 Hz, 1H, aromatic), 7.28--7.35 (m, 4H, aromatic), 7.38 (t, ^3^*J*~*H-F*~ = 7 Hz, 2H, aromatic), 7.47--7.50 (m, 3H, aromatic), 7.59--7.63 (m, 2H, aromatic), 7.77 (d, ^3^*J*~*H-F*~ = 13 Hz, 1H, aromatic), 8.04 (s, 1H, aromatic), 11.02 (s, 1H, COOH). IR (KBr) cm^−1^; ***ν*** 3580--3300 (COOH), 1726, 1620 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 20.7 (CH~3~), 49.0, 50.4 (CH~2~ piperazine), 52.3 (CH~2~), 75.7 (OCH~2~), 106.3, 108.8, 111.8 (d, ^3^*J*~C-F~ = 23.75 Hz), 117.9 (d, ^3^*J*~C-F~ = 23.75 Hz), 121.5, 126.4, 127.8, 128.1, 128.2, 128.7, 129.8 (d, ^1^*J*~C-F~ = 8.75 Hz), 132.2,136.3, 137.8, 138.6, 140.5, 145.5, 148.9, 151.2, 154.9, 163.0 (COOH), 169.0 (C=N), 173.0 (C=O). Anal. Calcd. For C~36~H~32~F~2~N~4~O~4~: C: 69.44; H: 5.18; N: 9.00; C: 69.62; H: 5.41; N: 9.22.

### 7-(4-(2-((Benzyloxy)imino)-2-(2,4-dichlorophenyl)ethyl)piperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (4x) {#Sec27}

Off-white powder, ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ (ppm): 2.62 (bs, 4H, piperazine), 3.02--3.08 (m, 4H, piperazine), 3.58 (s, 2H), 5.16 (s, 2H, NOCH~2~), 6.44 (d, ^4^*J*~*H-F*~ = 7 Hz, 1H, aromatic), 7.37 (d, *J* = 7 Hz, 1H, aromatic), 7.53 (t, ^3^*J*~*H-F*~ = 6.5 Hz, 2H, aromatic), 7.63 (d, *J* = 9 Hz, 1H, aromatic), 7.72--7.78 (m, 5H, aromatic), 7.96--8.01 (m, 3H, aromatic), 8.01 (s, 1H, aromatic), 8.63 (s, 1H, aromatic), 12.85 (s, 1H, COOH). IR (KBr cm^−1^), *ṽ* = 3580--3300 (OH), 1715, 1619 (C=O). ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ (ppm): 45.0, 49.0 (CH~2~ piperazine), 51.7 (CH~2~), 76.0 (OCH~2~), 106.8, 111.1 (d, ^3^*J*~C-F~ = 22.5 Hz), 117.9 (d, ^3^*J*~C-F~ = 22.5 Hz), 119.0, 128.3, 130.6, 129.8 (d, ^1^*J*~C-F~ = 8.75 Hz), 132.2, 132.2, 136.3, 137.8, 138.6, 146.0, 148.9, 151.2, 154.9, 166.1 (COOH), 172.0 (C=N), 176.43 (C=O). Anal. Calcd. For C~35~H~28~Cl~2~F~2~N~4~O~4~: C: 62.05; H: 4.17; N: 8.27; C: 62.32; H: 4.36; N: 8.55.

Pharmacology {#Sec28}
============

Conventional agar-dilution method was used to determine the minimum inhibitory concentrations (MIC) of the synthesized compounds (**4a-x**), according to previously reported method \[[@CR26]\]. The results of antibacterial testing of *N*-\[2-(aryl-3-yl) ethyl\] piperazinyl quinolones **4** and their oxime derivatives **(4 g-x)** against a panel of selected Gram-positive \[*Staphylococcus aureus* ATCC 6538p, *Micrococcus luteus*, ATCC 1110, *Staphylococcus epidermidis* ATCC 12228, *Bacillus subtilis* ATCC 6633\], and Gram-negative \[*Escherichia coli* ATCC 8739, *Klebsiella pneumoniae* ATCC 10031 and *Pseudomonas aeruginosa* ATCC 9027, *Serratia marcescens* PTCC 1111\] bacteria are reported in Table [2](#Tab2){ref-type="table"}, compared to the reference drug sarafloxacin.

Two-fold dilution of compounds **4a-x** and positive control were done by dissolving 6.4 mg in dimethylsulfoxide (DMSO; 1 mL), which were diluted with water (9 mL) and added to molten Mueller-Hinton (MH) agar to give a final concentration of 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.13, 0.06, 0.03, 0.015, 0.0075 and 0.00375 μg/mL^−1^. Petri dishes were incubated with 1--5 × 10^4^ colony forming units (cfu) at 35--37 °C and examined after 18 h. The lowest concentration of the agent, which completely led to the visible growth inhibition on the Petri dish of the microorganisms was determined as the minimum inhibitory concentration (MIC).

Results and discussion {#Sec29}
======================

Chemistry {#Sec30}
---------

The synthetic pathways for the synthesis of intermediates **(2 g-r)**, the target compounds **(4a-x)** and their physical data are shown in Table [1](#Tab1){ref-type="table"}. Compounds **(2 g-r)** were prepared by stirring the ketone analogues with excess amounts of hydroxylamine, *O*-methylhydroxylamine and *O*-benzylhydroxylamine hydrochloride salts in methanol at room temperature \[[@CR20]--[@CR22]\]. Then, the reaction of **3** with compounds **(1a-f)** and **(2 g-r)** in DMF in the presence of NaHCO~3~ at 25 °C afforded corresponding *N*-\[2-(aryl-3-yl) ethyl\] piperazinyl quinolones **(4a-x)** which was purified by recrystallization from methanol-chloroform.Table 1Synthetic pathway and physical data of target compounds **4a-x**^a^Isolated yields

Antibacterial activity {#Sec31}
----------------------

The activity of synthesized compounds (**4a-x)** were evaluated against Gram-positive \[*Staphylococcus aureus* ATCC 6538p, *Micrococcus luteus*, ATCC 1110, *Staphylococcus epidermidis* ATCC 12228 and *Bacillus subtilis* ATCC 6633\] and Gram-negative \[*Escherichia coli* ATCC 8739, *Klebsiella pneumoniae* ATCC 10031 and *Pseudomonas aeruginosa* ATCC 9027 and *Serratia marcescens* PTCC 1111\] using conventional agar-dilution method.

The MIC (minimum inhibitory concentration) values were determined against the eight strains and summarized in Table [2](#Tab2){ref-type="table"}. As indicated in this table, it was concluded that compound **4 g** exhibited comparable results with sarafloxacin against *S. aureus, S. epidermidis* and *B. subtilis*, while other synthesized compounds showed moderate to poor activity against these bacteria. The obtained data suggested that the good activities were obtained in case of Gram-positive microorganism, *Bacillus subtilis*. In accordance with antibacterial results, among ketones, *O*-methyloximes and *O*-benzyloximes derivatives of target compounds, lower susceptibilities (higher MICs) were observed in *O*-methyloxime and *O*-benzyloxime-incorporated derivatives. Thus, *O*-methyloxime and *O*-benzyloxime moiety diminished the activity against both Gram-positive and Gram-negative bacteria. The most potent compound against Gram-positive (compound **4 g**) belongs to the oxime series.Table 2*In vitro* antibacterial activities of compounds **4a-x** in Comparison to sarafloxacin (MICs in μg/mL)

Conclusions {#Sec32}
===========

In conclusion, a series of FQ derivatives are synthesized and evaluated for their biological activity. Compound **4 g** showed good activity against *S. aureus*, *S. epidermidis* and *B. subtilis*. It was concluded that the introduction of bulky moieties on piperazine ring at C-7 position of fluoroquinolones reduced the antibacterial activities against both Gram-negative and Gram-positive bacteria. In addition, the antibacterial activity of target compounds could not be improved by *O*-methylation or *O*-benzylation of oxime derivatives.
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